TL1A increased IL-6 production on fibroblast-like synoviocytes by preferentially activating TNF receptor 2 in rheumatoid arthritis.

[1]  Wei Wei,et al.  Ginsenoside metabolite compound K exerts joint-protective effect by interfering with synoviocyte function mediated by TNF-α and Tumor necrosis factor receptor type 2. , 2016, European journal of pharmacology.

[2]  Y. Xiang,et al.  Serum Levels of IL-6 and TNF-α May Correlate with Activity and Severity of Rheumatoid Arthritis , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[3]  S. Siakavellas,et al.  Tumor Necrosis Factor–like Cytokine TL1A and Its Receptors DR3 and DcR3: Important New Factors in Mucosal Homeostasis and Inflammation , 2015, Inflammatory bowel diseases.

[4]  P. Sfikakis,et al.  The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases. , 2015, Seminars in arthritis and rheumatism.

[5]  C. Darrieutort-Laffite,et al.  IL-1β and TNFα Promote Monocyte Viability through the Induction of GM-CSF Expression by Rheumatoid Arthritis Synovial Fibroblasts , 2014, Mediators of inflammation.

[6]  P. Tak,et al.  Citrullination of Epithelial Neutrophil–Activating Peptide 78/CXCL5 Results in Conversion From a Non–Monocyte‐Recruiting Chemokine to a Monocyte‐Recruiting Chemokine , 2014, Arthritis & rheumatology.

[7]  R. Liu,et al.  TL1A increased the differentiation of peripheral Th17 in rheumatoid arthritis. , 2014, Cytokine.

[8]  L. Abasolo,et al.  Alternative splicing and proteolytic rupture contribute to the generation of soluble IL-6 receptors (sIL-6R) in rheumatoid arthritis. , 2013, Cytokine.

[9]  X. Sun,et al.  Elevated serum and synovial fluid TNF-like ligand 1A (TL1A) is associated with autoantibody production in patients with rheumatoid arthritis , 2013, Scandinavian journal of rheumatology.

[10]  Wei Wei,et al.  BF02, a recombinant TNFR2 fusion protein, alleviates adjuvant arthritis by regulating T lymphocytes in rats , 2013, Acta Pharmacologica Sinica.

[11]  Lyubomir G. Nashev,et al.  Mineralocorticoid and glucocorticoid receptors differentially regulate NF-kappaB activity and pro-inflammatory cytokine production in murine BV-2 microglial cells , 2012, Journal of Neuroinflammation.

[12]  Miho Suzuki,et al.  IL-6/IL-6 receptor system and its role in physiological and pathological conditions. , 2012, Clinical science.

[13]  Roberto Giacomelli,et al.  Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? , 2011, Autoimmunity reviews.

[14]  M. Kamal,et al.  Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA , 2011, Clinical Rheumatology.

[15]  G. Firestein,et al.  Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis , 2010, Immunological reviews.

[16]  J. Fikes,et al.  Role of TL1A in the Pathogenesis of Rheumatoid Arthritis1 , 2009, The Journal of Immunology.

[17]  M. Hashizume,et al.  IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. , 2008, Rheumatology.

[18]  P. Sfikakis,et al.  Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. , 2008, Clinical immunology.

[19]  E. Shevach,et al.  The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. , 2008, Immunity.

[20]  A. Koch,et al.  Mechanisms of Disease: angiogenesis in inflammatory diseases , 2007, Nature Clinical Practice Rheumatology.

[21]  R. Scrivo,et al.  The Immunology of Rheumatoid Arthritis , 2007, Annals of the New York Academy of Sciences.

[22]  S. Targan,et al.  The T Cell Costimulator TL1A Is Induced by FcγR Signaling in Human Monocytes and Dendritic Cells , 2007, The Journal of Immunology.

[23]  D. Noonan,et al.  Cytokines and chemokines as regulators of angiogenesis in health and disease. , 2006, Current pharmaceutical design.

[24]  Ju-Young Kim,et al.  IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-κB- and PI3-kinase/Akt-dependent pathways , 2004, Arthritis research & therapy.

[25]  Jun Zhang,et al.  TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. , 2002, Immunity.

[26]  O. Nadiv,et al.  Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in inflammation processes. , 2001, Arthritis and rheumatism.

[27]  D. Goeddel,et al.  A death-domain-containing receptor that mediates apoptosis , 1996, Nature.

[28]  N. Udagawa,et al.  Interleukin‐6 and soluble interleukin‐6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast‐like cell formation , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  T. Taniguchi,et al.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.

[30]  A. Koch,et al.  Successes and failures of chemokine-pathway targeting in rheumatoid arthritis , 2016, Nature Reviews Rheumatology.

[31]  S-Y Hwang,et al.  Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and p38 MAPK-dependent signalling pathways. , 2007, Rheumatology.

[32]  T. Kishimoto.  Interleukin-6: from basic science to medicine--40 years in immunology. , 2005, Annual review of immunology.

[33]  B. Kirkham,et al.  Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. , 1992, The Journal of rheumatology.